On August 31, 2026 Chimigen Biomedical reported the early clinical trial of KMV002 was successfully held in Chengdu, Sichuan. KMV002 is KemiBio’s first pipeline in the oncology field to enter the clinical research stage.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This trial aimed to evaluate the safety, tolerability, and immunogenicity of KMV002 in patients with metastatic androgen pathway-regulated resistance (mAPMR). It was hosted by the Department of Urology, West China Hospital of Sichuan University, with West China Hospital serving as the trial site. Professor Yang Lu, Deputy Director of the Department of Urology and Project PI of West China Hospital, Ms. Niu Qian, General Manager of West China Clinical Research Center Co., Ltd., Dr. Shi Yuenian, Chairman and CEO of KemiBio, and Dr. Lu Hanxin, CSO of KemiBio, attended the meeting.

KMV002 is an immunotherapy pipeline developed by KemiBio for mCRPC. Driven by the company’s core technology platform—SynNeogen—KMV002 utilizes AI-assisted engineering to achieve highly efficient targeted delivery of FcR-mediated dendritic cells (DCs), thereby activating cross-antigen presentation and specific CD8+ T cell immune responses, ultimately achieving the therapeutic goal of treating "cold tumors" of the prostate. In previous studies, KMV002 has demonstrated good therapeutic efficacy and safety in multiple animal models.

(Press release, Chimigen Biomedical, AUG 31, 2026, View Source [SID1234673519])